Vaxcyte officer plans sale of 3,477 shares

Vaxcyte, Inc. (PCVX) has a notice under Rule 144 for planned sales of common stock for the account of officer James Wassil, with UBS Financial Services, Inc. as broker.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) has a notice under Rule 144 for planned sales of common stock for the account of officer James Wassil, with UBS Financial Services, Inc. as broker. The notice covers the potential sale of 3,477 shares of common stock with an aggregate market value of $209,628.33. Vaxcyte reports 148,805,278 shares of common stock outstanding as of September 1, 2026. In the prior three months, Wassil reported sales of 2,250 shares on each of June 1, July 1, and August 3, 2026, for aggregate prices of $111,416.62, $126,735.98, and $121,194.45, respectively.

Key Figures

Shares to be sold: 3,477 shares Aggregate market value of shares to be sold: $209,628.33 Shares outstanding: 148,805,278 shares +5 more

8 metrics

Shares to be sold 3,477 shares Potential Rule 144 sale of Vaxcyte common stock

Aggregate market value of shares to be sold $209,628.33 Value associated with 3,477 shares covered by the notice

Shares outstanding 148,805,278 shares Vaxcyte common shares outstanding as of September 1, 2026

RSU vesting shares 1,227 shares RSU vest on August 31, 2026 related to securities to be sold

Stock option exercise shares 2,250 shares Exercise of stock options on September 1, 2026 related to securities to be sold

June 1, 2026 aggregate sale price $111,416.62 Sale of 2,250 shares on June 1, 2026

July 1, 2026 aggregate sale price $126,735.98 Sale of 2,250 shares on July 1, 2026

August 3, 2026 aggregate sale price $121,194.45 Sale of 2,250 shares on August 3, 2026

Key Terms

Rule 144, RSU Vest, Exercise of stock options, attorney-in-fact, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU Vest financial

"Common | 08/31/2026 | RSU Vest | Issuer |"

Exercise of stock options financial

"Common | 09/01/2026 | Exercise of stock options | Issuer |"

attorney-in-fact regulatory

"UBS Financial Services Inc, as attorney-in-fact for James Wassil"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Vaxcyte, Inc. (PCVX)?

The filing reports that company officer James Wassil may sell up to 3,477 shares of Vaxcyte common stock under Rule 144, with an aggregate market value of $209,628.33. It is a notice of a potential sale, not a confirmation that sales have occurred.

How many Vaxcyte (PCVX) shares are covered by this Rule 144 notice?

The notice covers a potential sale of 3,477 shares of Vaxcyte common stock, with an aggregate market value listed as $209,628.33. These shares relate to RSU vesting of 1,227 shares and the exercise of stock options for 2,250 shares.

How many Vaxcyte (PCVX) shares are outstanding according to this filing?

Vaxcyte reports 148,805,278 shares of common stock outstanding as of September 1, 2026. This figure provides context for the scale of the 3,477 shares that may be sold under the Rule 144 notice.

What prior Vaxcyte (PCVX) stock sales by James Wassil are disclosed?

The filing lists three prior transactions by James Wassil: 2,250 shares sold on each of June 1, 2026 for $111,416.62, July 1, 2026 for $126,735.98, and August 3, 2026 for $121,194.45 in aggregate sale prices.

What types of equity awards are involved in the Vaxcyte (PCVX) Form 144 filing?

The notice indicates that the 3,477 shares associated with the planned sale arise from an RSU vest of 1,227 shares on August 31, 2026 and an exercise of stock options for 2,250 shares on September 1, 2026, with the option exercise to be paid in cash.

Who is the broker for the proposed Vaxcyte (PCVX) share sale under Rule 144?

The broker listed is UBS Financial Services, Inc., located at 11 Madison Ave, New York. UBS is named as attorney-in-fact for James Wassil and is identified in connection with the proposed sale of 3,477 Vaxcyte common shares on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:11 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:09 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001813798
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vaxcyte, Inc.
SEC File Number	001-39323
Address of Issuer	825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CALIFORNIA 94070
Phone	650-837-0111
Name of Person for Whose Account the Securities are To Be Sold	Wassil Jim
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	3477	209628.33	148805278	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/31/2026	RSU Vest	Issuer			1227	08/31/2026	NA
Common	09/01/2026	Exercise of stock options	Issuer			2250	09/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	06/01/2026	2250	111416.62
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	07/01/2026	2250	126735.98
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	08/03/2026	2250	121194.45

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for James Wassil
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)